Finance

Lists
Outlook: 75.0% bullish·0.0% bearish
Go to analysis
INCY:NASDAQ
Incyte Corp
$113.25
+0.16%
(+0.18) 1D
$113.36
+0.10% (+0.11)
After hours
Closed: Oct 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INCY...
Open
$113.19
High
$114.38
Low
$112.71
Mkt. cap
22.96B
Avg. vol.
1.69M
Volume
1.19M
P/E ratio
14.43
52-wk high
$132.60
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
Open
$113.19
High
$114.38
Low
$112.71
Mkt. cap
22.96B
Avg. vol.
1.69M
Volume
1.19M
P/E ratio
14.43
52-wk high
$132.60
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
News stories
From web sources and news partners
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteincyte.com
Analyst ratings
Based on 21 analysts giving stock ratings to INCY in the past 3 months
Buy
Buy
11
Hold
10
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for INCY in the last 3 months.
Highest
Current $113.25
$157.00 (+38.63%)
Average
$131.70 (+16.29%)
Lowest
$104.00 (-8.17%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$152.00
+34.2%
10/19/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$114.00
+0.7%
10/16/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$152.00
+34.2%
10/16/2026
Derek Archila
Wells Fargo
Hold
Maintained
$128.00
+13%
10/15/2026
Srikripa Devarakonda
Truist Financial
Hold
Maintained
$115.00
+1.5%
10/14/2026
Etzer Darout
Barclays
Buy
Maintained
$139.00
+22.7%
10/13/2026
Evan Seigerman
BMO Capital
Hold
Maintained
$130.00
+14.8%
10/12/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$140.00
+23.6%
10/09/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$157.00
+38.6%
10/05/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
$123.00
+8.6%
09/28/2026
Jeffrey Walch
Bernstein
Hold
Maintained
$104.00
-8.2%
09/25/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/19/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$130.00
+14.8%
08/17/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$137.00
+21%
08/03/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$155.00
+36.9%
08/03/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$118.00
+4.2%
07/29/2026
Ashwani Verma
UBS
Hold
Maintained
$113.00
-0.2%
07/28/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$150.00
+32.5%
07/28/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$119.00
+5.1%
07/29/2026
Jay Olson
Oppenheimer
Buy
Maintained
$120.00
+6%
07/28/2026
Marc Frahm
TD Cowen
Buy
Maintained
$138.00
+21.9%
07/28/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$105.00
-7.3%
05/20/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$130.00
+14.8%
05/04/2026
Unknown Analyst
Argus Research
Buy
Maintained
$115.00
+1.5%
04/30/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
$94.00
-17%
03/15/2026
Unknown Analyst
Evercore ISI
Hold
Maintained
$110.00
-2.9%
03/05/2026
Next call in 10 days
Thu, Oct 29, 2:00 PM
Fiscal period
Q3 2026
- / -$3.84
Revenue / Est. (USD)
- / 1.48B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.37B
1.51B
1.27B
1.67B
Cost of goods sold
605.58M
732.55M
620.43M
621.91M
Cost of revenue
605.58M
732.55M
620.43M
621.91M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
328.29M
388.96M
327.06M
350.72M
Operating expense
328.29M
388.96M
327.06M
350.72M
Total operating expenses
933.87M
1.12B
947.49M
972.63M
Operating income
432.11M
385.32M
325.19M
701.41M
Other non operating income
3.25M
4.22M
1.75M
5.26M
EBT including unusual items
482.31M
389.94M
343.60M
751.51M
EBT excluding unusual items
461.55M
419.71M
360.06M
744.21M
Income tax expense
58.14M
90.66M
40.27M
165.91M
Effective tax rate
12.05%
23.25%
11.72%
22.08%
Other operating expenses
-
-
-
-
Net income
424.17M
299.28M
303.33M
585.60M
Net profit margin
31.05%
19.86%
23.83%
34.98%
Earnings per share
2.26
1.80
1.81
3.09
Interest and investment income
26.78M
30.75M
33.69M
38.12M
Interest expense
-592.00K
-582.00K
-569.00K
-582.00K
Net interest expenses
26.19M
30.17M
33.12M
37.54M
Depreciation and amortization charges
-
-
-
-
EBITDA
456.13M
409.30M
348.99M
727.89M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps